Ascendis Pharma A/S Q4 Earnings Call Highlights

Outside the U.S., Ascendis said YORVIPATH is available commercially or through named patient programs in more than 30 countries , with full commercial reimbursement in four Europe Direct markets and two international markets . In Japan, partner Teijin launched YORVIPATH commercially in November 2025. Looking ahead, management said it expects full commercial launches in 10 additional new countries in 2026 .In the U.S., management said access continued to expand, with more than 5,300 patients prescribed YORVI ...